Teva faces EU antitrust probe over MS drug Copaxone

The European Commission has formally opened an antitrust investigation into Teva, which will assess whether the pharma company illegally delayed launches and use of generic versions of its

AstraZeneca breathes sigh of relief as court blocks US Symbi...

A US court has upheld AstraZeneca’s patents on its respiratory drug Symbicort, blocking cheaper competition for the ageing blockbuster.

EU fines Teva and Cephalon €60.5m for 'pay for delay' scheme

The European Union has fined Teva and its neurology unit Cephalon €60.5 million for an elaborate “pay for delay” scheme that prevented cheaper generic competition for its sleep disorder dru

Amgen's cancer biosimilars stay on US market as court battle...

Amgen has scored yet another home run in the US courts, this time seeing off a legal challenge from Genentech, which was trying to block it from launching two cut-price cancer biosimilars. 

Amgen wins latest round in legal tussle over Enbrel patents

Amgen’s reputation as a fearsome adversary in the courtroom remains intact after it won the latest round in a legal tussle with Sandoz over the patent covering the blockbuster inflammatory

AbbVie won’t enforce patents for COVID-19 drug candidate Kal...